5) Watanabe M, Yahagi T, Shirayama T, Miyake K, Kotani H, Ogawa T, Matsuzaki
K:
6) Uehara S, ida Y, da-Tanaka M, Goto M, Kawai K, Yamamoto M, Higuchi Y,Ito
S, Takahashi R, Kamimura H, Ito M, Yamazaki H, Oshimura M, Kazuki Y, Suemizu
H:
7) Kazuki Y, Gao FJ, Yamakawa M, Hirabayashi M, Kazuki K, Kajitani N, Miyagawa-Tomita
S, Abe S, Sanbo M, Hara H, Kuniishi H,Ichisaka S, Hata Y, Koshima M, Takayama
H, Takehara S, Nakayama Y, Hiratsuka M, Iida Y, Matsukura S, Noda N, Li
Y, Moyer AJ, Cheng B, Singh N, Richtsmeier JT, Oshimura M, Reeves RH: A
transchromosomic rat model with human chromosome 21 shows robust Down syndrome
features. Am J
Hum Genet. 2022, Feb 3;109(2):328-344.
8) Uehara S, Higuchi Y, Yoneda N, Kawai K, Yamamoto M, Kamimura H, Iida
Y, Oshimura M, Y Kazuki Y, Yamazaki H, Hikita H, Takehara T, Suemizu H::
An improved TK-NOG mouse as a novel platform for humanized liver that overcomes
limitations in both male and female animals. Drug Metab Pharmacokinet. 2022, Feb;42:100410.
[2021]
1) Kartika ID, Kotani H, Iida Y, Koyanagi A, Tanino R, Harada M. Protective role of cytoplasmic
p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor-treated senescence in breast cancer cells. Cancer Medicine, 2021;10(24):8988-8999.
[2020]
1) Tanino R, Amano Y, Tong X, Sun R, Tsubata Y, Harada M, Fujita Y, Isobe
T. Anticancer activity of ZnO nanoparticles against humna small-cell lung
cacner in an orthotopic mouse model. Molecular Cancer Therapeutics, 19: 502-512, 2020
2) Okimoto T, Kotani H, Iida Y, Koyanagi A, Tanino R, Tsubata Y, Isobe T,
Harada M. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune
cells. Cancer Science 111:1910-1920, 2020.
3)
Satoh Y, Kotani H, Iida Y, Taniura T, Notsu Y, Harada M. Supplementation of L-arginine boosts the therapeutic efficacy of anticancer
chemoimmunotherapy. Cancer Science 2020, 111;2248-2258, doi: 10.1111/cas.14490.
4)
Komohara Y, Harada M, Ohnishi K, Kumamoto K, Nakayama T. PD-L1 expression
in regional lymph nodes and predictable roles in anti-cancer immune responses.
Journal of Clinical and Experimental Hematopathology, 2020. July 8. DOI: 10.3960/jslrt.20015
5) Iida Y, Yoshikawa R, Murata A, Kotani H, Kazuki Y, Oshimura M, Matsuzaki
Y, Harada M. Local injection of CCL19-expressing mesenchymal stem cells
augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration
of immune cells. Journal of ImmunoTherapy of Cancer
6) Taniura T, Iida Y, Kotani H, Ishitobi K, Tajima Y, Harad M. Immunogenic chemotherapy in two murine colon cancer models.
Cancer Science,
[2019]
1) Inao T, Kotani H, Iida Y, Kartika ID, Okimoto T, Tanino R, Shiba E, Harada
M. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. Cancer Science, 110:2690-2699, 2019.
2) Komohara Y, Harada M. Potential
mechanisms of spontaneous regression in patients with B-cell lymphoma: the significance of co-stimulatory molecules in lymphoma cells. Journal
of Clinical and Experimental Hematopathology, 59:207-210, 2019.
[2018]
1) Komohara Y, Harada M. Potential
mechanisms of spontaneous regression in patients with B-cell lymphoma: the significance of co-stimulatory molecules in lymphoma cells. Journal of Clinical and Experimental Hematopathology, 59:207-210, 2019.
2) Tanino R, Tsubata Y, Harashima N, Harada M, Isobe T. Novel drug-resistance
mechanisms of pemetrexed-treated non-small cell lung cancer. Oncotarget, 9:16807-16821. 2018. doi: 10.18632/oncotarget.24704.
3)Inao T, Iida Y, Moritani T, Okimoto T, Tanino R, Kotani H, Harada M. Bcl-2
inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.
Oncotarget, 9:25545-25556, 2018. doi: 10.18632/oncotarget.25370.
[2017]
1) Minami T, Matsumoto N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura
K, Harashima N, Harada M, Uemura H. Hypoxia-inducing factor (HIF)-1a -derived peptide capable
of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. International Immunopharmacology, 44: 197-202, 2017.doi: 10.1016/j.intimp.2017.01.014.
2) Harashima N, Takenaga K, Akimoto M, Harada M. HIF-2a dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating
survivin expression. Oncotarget, 8: 42887 – 42900, 2017. doi:
10.18632/oncotarget.17157.
3)
Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M. Contrasting effects of cyclophosphamide on anti-CTLA-4 blockade therapy in two tumor mouse models. Cancer Science, 108: 1974 – 1984, 2017. doi: 10.1111/cas.13337.
[2016]
1) Ogura T, Tanaka Y, Tamaki H, Harada M. Docetaxel induces Bcl-2- and pro-apoptotic
caspase-independent cell death in human prostate cancer DU145 cells. International Journal of Oncology, 48: 2330-2338, 2016.
.
2) Ishikawa S, Matsui Y, Wachi S, Yamaguchi H, Harashima N, Harada M. Age-associated impairment of antitumor immunity in carcinoma-bearing mice
and restoration by oral administration of Lentinula edodes mycelia extract.
Cancer Immunology, Immunotherapy, 65;961-972, 2016.
3) Harada M. [Commentary] Immunogenic chemotherapy with cyclophosphamide and gemcitabine. Immunotherapy Open Access, 2 (3) 1000124, 2016. doi: 10.4172/2471-9552.1000124.
[2015]
1) Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M. Sorafenib enhances the anti-tumor effects of anti-CTLA4 antibody in by inhibiting myeloid-derived suppressor cells. Oncology Reports, 33; 2947-2953, 2015.
2) Minami
T, Minami T, Shimizu N, Yamamoto Y, De Velasco M A, Nozawa M, Yoshimura K,
Harashima N, Harada M, Uemura H. New polycomb group protein enhancer of
zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive
cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype
alleles.International Immunopharmacology, 26:
133-138, 2015.
3) Zhang M, Harashima N, Moritani T, Huang W, Harada M. The roles of ROS and caspases in TRAIL-induced apoptosis and necroptosis
in human pancreatic cancer cells. PLOS One, 10: e0127386, 2015.
4) Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Identification
of programmed death ligand 1-derived peptides capable of inducing cancer-reactive
cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. Journal of Immunotherapy, 38: 285-291, 2015.
5) Hari Y, Harashima N, Tajima Y, Harada M. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic
cancer cells to TRAIL. Oncotarget, 6: 41902-15. 2015.
6) Tongu M, Harashima N, Tamada K, Chen L, Harada M. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state. Cancer Science
106: 9-17, 2015.
7) Umemoto Y, Okano S, Matsumoto Y, Matsumoto Y, Nakagawara H, Matono R, Yoshiya
S, Yamashita Y, Yoshizumi T, Ikegami T, Soejima Y, Harada M, Aishima S,
Oda Y, Shirabe K, Maehara Y. Prognostic impact of programmed cell death
1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular
carcinoma after curative hepatectomy. Journal of Gastroenterology. 50: 65 - 75, 2015.
[2014]
1) Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura
K, Harashima N, Harada M, Uemura H. Identification of erythropoietin receptor-derived
peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes
from HLA-A24+ patients with renal cell carcinoma. International Immunopharmacology, 20: 59-65, 2014.
2) Harashima N, Minami T, Uemura H, Harada M. Transfection of poly(I:C) can induce ROS-triggered apoptosis and IFN-b-mediated growth arrest in human renal cell carcinoma cells via innate
adjuvant receptors and the 2-5A system. Molecular Cancer, 13: 217, 2014.
3) Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora
K, Harada M. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel
and promotes unexpected apoptosis under caspase-9 inhibition. Oncotarget, 5:11399-412, 2014.
4) Harada M. Effects of metronomic chemotherapy on immunity, in "Metronomic chemotherapy" (eds) Bocci G, Francis G. Springer, p 39 - 51, 2014.
[2013]
1) Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, Harada
M. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine
can induce anti-tumor T cell immunity in vivo. Cancer Immunology Immunotherapy, 62: 383-91, 2013.
2) Monma H, Harashima N, Inao T, Okano S, Tajima Y, Harada M. The HSP70
and autophagy inhibitor pifithrin-mu enhances TRAIL-induced antitumor effects
on human pancreatic cancer. Molecular Cancer Therapeutics, 12: 341-351, 2013.
3) Sekihara M, Harashima N, Tongu M, Tamaki Y, Uchida N, Inomata T, Harada M. Pifithrin-mu, an inhibitor of heat-shock protein 70, can increase the antitumor effects of hyperthermia against human prostate cancer cells. PLoS One, 8(11):e78772. 2013.
4) Mishiro T, Kusunoki R, Otani A, Ansary MMU, Tongu M, Harashima N, Yamada
T, Sato S, Amano Y, Itoh K, Ishihara S, Kinoshita Y. Butyric acid attenuates
intestinal inflammation in murine DSS-induced colitis model via milk fat
globule-EGF factor 8. Laboratory Investigation, 93: 834-843, 2013.
[2012]
1) Oshiro K, Kohama H, Umemura M, Uyttenhove C, Inagaki-Ohara K, Arakawa T, Harada M, Nakae S, Iwakura Y, Nishimaki T, Matsuzaki G. Interleukin-17A is involved in enhancement of tumor progression in murine intestine. Immunobiology, 217: 54-60, 2012.
2) Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of
PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and
growth arrest of human prostate cancer cells. Cancer Immunology Immunotherapy, 61:667-676, 2012.
3) Tanaka K, Matsui Y, Ishikawa S, Kawanishi T, Harada M. Oral ingestion
of Lentinula edodes mycelia extract can restore the antitumor T cell response
of mice inoculated with colon-26 cells into the subsersal space of the
cecum. Oncology Reports, 27: 325-332, 2012.
4) Inao T, Harashima N, Monma H, Okano S, Itakura M, Tanaka T, Tajima Y, Harada M. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer.Breast Cancer Research and Treatment, 134: 89-100, 2012.
5) Tanaka K, Ishikawa S, Matsui Y, Kawanishi T, Tamasada M, Harashima N,
Harada M. Combining a peptide vaccine with oral ingestion of Lentinula
edoles mycelia extract enhances anti-tumor activity in B16 melanoma-bearing
mice. Cancer Immunology Immunotherapy, 61: 2143-2152, 2012.
[2011]
1) Okano S, Yonemitsu Y.Shirabe K, Kakeji Y, Maehara Y, Harada M, Yoshikai
Y, Inoue M, Hasegawa M, Sueisi K. Provision of continuous maturation signaling
to dendritic cells by RIG-1-stimulating cytosolic RNA synthesis od Sendai
virus. Journal of Immunology, 186: 1828-1839, 2011.
2) Tanaka K, Ishikawa S, Matsui Y, Tamesada M, Harashima N, Harada M. Oral ingestion of Lentinus edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. Cancer Science, 102: 516-521, 2011.
[2010]
1) Tongu M, Harashima N, Yamada T, Harada T, Harada M. Immunogenic chemptherapy
with cyclophosphamide and doxorubicin against established murine carcinma.
Cancer Immunology Immunotherapy, 59: 769-777, 2010.
2) Harada M, Harashima N.[Editorial] 'Sterile' inflammation and autophagy
in cancer immunotherapy. Immunotherapy, 2: 599-601, 2010.
[2009]
1) Hamaguchi M, Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Teshima T, Harada M, Yoshikai Y, Naito S. Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the anitumor effect after cyclophosphamide-using nonmyeloablative allogenenic hematopoietic cell transplantation in mice. Cancer Science, 100: 138-143, 2009.
2) Shimizu Y, Takamori A, Utsunomiya A, Kurimura M, Yamano Y, Hishizawa M,Hasegawa A, Kondo F, Kurihara K, Harashima N, Watanabe T, Okamura J, Masuda
T, Kannagi M. Impaired Tax-specific T-cell responses with insufficient
control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering
stages. Cancer Science, 100: 481-489, 2009.
3) Kondo M, Murakawa Y, Harashima N, Kobayashi S, Yamaguchi S, Harada M. Roles
of proinflammatory cytokines and the Fas/FasL interaction in pathogenesis
of inflammatory myopathies. Immunology, 128: e589-e599, 2009.
4) Komohara Y, Takemura K, Lei XF, Sakashita N, Harada M, Suzuki H, Kodama
T, Takeya M.
Delayed growth of EL4 lymphoma in SR-A-deficient mice is due to up-regulation
of nitric oxide and IFN-g production by tumor-associated macrophages. Cancer Science, 100: 2160-2166, 2009.
[2008]
1) *Takahashi Y, *Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy,
JP, Hanada K,Mena O, Kurlander R, Tawab A, Srinivasan R, Lundqvist A, Malinzak
E, Geller N, Lerman MI, Childs RW. Regression of human kidney cancer following
allogeneic stem cell transplantation is associated with recognition of
an HERV-E antigen by T cells. (*equally contributed) Journal of Clinical Investigation, 118:
1099-1109, 2008.
2) Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima
K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S. Posttransplant
administration of cyclophosphamide and donor lymphocyte infusion induces
potent antitumor immunity to solid tumor. Clinical Cancer Research, 14; 2833-2840, 2008
3) Jin M, Komohara Y, Shichijo S, Harada M, Yamanaka R, Miyamoto S, Nikawa J, Itoh K, Yamada A. Identification of Eph6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncology Reports, 19; 1277-1283, 2008.
4) Komatsu N, Harada M, Nakagawa M, Tanaka Y, Ono T, Gohara S, Ohkubo K, Itoh
K. A correlation between symptom severity and unbalanced reactive IgA production
in Japanese ceder pollinosis patients. Asian Pacific Journal of Allergy and Immunology, 26: 97-104, 2008
[2007]
1) Harada M, Ishihara Y, Itoh K, Yamanaka R. Kinesin superfamily protein-derived
peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes
in HLA-A24+ glioma patients. Oncology Reports, 17: 629-636, 2007.
2) Eto M, Harano M, Tatsugami K, Harada M, Kamiryo Y, Kiyoshima K, Hamaguchi
M, Tsuneyoshi M, Yoshikai Y, Naito S. Cyclophosphamide-using nonmyeloablative
allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host
disease. Clinical Cancer Research, 13: 1029-1035, 2007.
3) Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K,
Matsuoka K. Identification of target antigens in specific immunotherapy for renal cell carcinoma. Journal of Urology, 177: 1157-1162, 2007.
4) Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh
K, Harada M.
Identification of SART3-derived peptides having the potential to induce
cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with
HLA-A3 supertype alleles. Cancer Immunology Immunotherapy, 56: 689-698, 2007.
5) Matsueda S, Takedatsu H, Sasada T, Azuma K, Noguchi M, Shichijo S, Itoh
K, Harada M. New peptide vaccine candidates for epithelial cancer patients
with HLA-A3 supertype allelels. Journal of Immunotherapy, 30: 274-281, 2007.
6) Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M,
Suekane S, Itoh K, Matsuoka K. Combination therapy of personalized peptide vaccination and low-dose estramustine
phosphate for metastatic hormone refractory prostate cancer patients: An
analysis of prognostic factors in the treatment. Oncology Research, 16: 341-349, 2007.
7) Noguchi M, Yao A, Harada M, Nakashima O, Itoh K, Matsuoka K. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate, 67, 933-942, 2007.
8) Sato Y, Fujiwara T, Mine T, Shoumura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishida Y, Yamada A, Tanaka N, Itoh K, Harada M, Todo S. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracul derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Science, 98: 1113-1119, 2007.
9) Homma S, Komohara Y, Harada M, Saya H, Todo S, Itoh K, Noguchi M. Differential
levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen
receptor expressions in untreated prostate cancer cells: The robustness
of prostate cancer. Oncology Reports, 18: 343-346, 2007.
10) Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada
M. New peptides of the polycomb group protein enhancer of zeste homolog
2 (EZH2) with the potential to induce cancer-reactive cytotoxic T lymphocytes
in HLA-A2+ prostate cancer patients. Oncology Reports, 18: 1231-1237, 2007.
11) Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka
K, Itoh K.HLA-G as a target molecule in
specific immunotherapy against renal cell carcinoma. Oncology Reports, 18: 1463-1468, 2007.
12) Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada
A, Itoh K, Harada M. Identification of Lck-derived peptides applicable
to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype
alleles. British Journal of Cancer, 97; 1648-1654, 2007.